Topic: hematologic cancer
The deal, which features a $150 million equity investment and up to $1.1 billion in milestones, gives Incyte a stake in a near-approval CAR-T killer.
In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.
The data look competitive against Gilead’s Yescarta and Novartis’ Kymriah, leading analysts to predict Celgene will win FDA approval next year.
The deal grants Takeda rights to up to four programs, including natural killer cell therapies aimed at CD19 and BCMA.
China’s Antengene has raised another $120 million in a second-round financing, with partner Celgene contributing to the tally.
This year’s ASH saw multiple presentations on BCMA-targeting drugs, but Jefferies says Bluebird’s CAR-T bb2121 “is still leading the pack.”
Affimed has halted work on trials of its lead T cell engager AFM11 for blood cancers after a death and two life-threatening events.
Aptose is now racing to resume dosing blood cancer patients with the c-Myc inhibitor in the paused phase 1b study.
Biotech IPOs continue to come thick and fast this week, with CAR-T specialist Autolus the latest to list with an impressive $150 million raise.
U.S.-China biotech Xynomic Pharma has raised additional funding to take an HDAC inhibitor in-licensed last year into seven new cancer trials.